Under the terms of the agreement, ChemDiv will deploy the Discovery outSource platform for Orion’s discovery program, including chemical library, proprietary rational design, assay development and bioscreening. ChemDiv will screen rationally designed chemical libraries against Orion’s proprietary targets, and Orion will select hit series for subsequent lead optimization. The agreement provides options for expanding the discovery partnership.
Antti Haapalinna, director of nonclinical R&D, Orion Pharma, said: “Our partnership with ChemDiv complements our in-house discovery effort in this particular project.”
Nikolay Savchuk, president and CEO of ChemDiv, said: “Based on ChemDiv’s diligence and track record, we are confident of success and look forward to expansion of this collaboration in the near future.”